A rock and a hard place
The European Medicines Agency has refused approval for a new drug against Alzheimer's disease. Despite it having been approved by the US Food and Drug Administration, the EMA argued that it does not appear to be effective in two trials involving 3,000 patients.
Alzheimer's charities say they are disappointed by the decision because thousands of people are left with no treatment options.
Philippa Roxby, health reporter, BBC News
But, if the EMA's assessment of the trials is correct, and the drug truly isn't effective against the disease, then those thousands of people would have no treatment options anyway. At least, no effective treatment options.
Alzheimer's charities might better serve sufferers by championing treatment options that work—if any do—rather than clutching at straws. (pipe)